Norcantharidin ameliorates estrogen deficient-mediated bone loss by attenuating the activation of extracellular signal-regulated kinase/ROS/NLRP3 inflammasome signaling

Osteoporosis, characterized by reduced bone mass, aberrant bone architecture, and elevated bone fragility, is driven by a disruption of bone homeostasis between bone resorption and bone formation. However, up to now, no drugs are perfect for osteoporosis treatment due to different defects. In this s...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Guang, Xu, Huikang, Yao, Minjun, Yan, Shigui, Wu, Mengrui, Zhou, Chenhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669383/
https://www.ncbi.nlm.nih.gov/pubmed/36408264
http://dx.doi.org/10.3389/fphar.2022.1019478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669383/
https://www.ncbi.nlm.nih.gov/pubmed/36408264
http://dx.doi.org/10.3389/fphar.2022.1019478

Ejemplares similares